{"id":4299,"date":"2017-08-12T11:01:57","date_gmt":"2017-08-12T11:01:57","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/2017\/08\/12\/feasibility-of-deep-local-hyperthermia-treatment-in-conjunction-with-standard-cancer-treatments-and-patterns-of-response-esho\/"},"modified":"2025-09-05T07:35:19","modified_gmt":"2025-09-05T07:35:19","slug":"klinikinis-tyrimas-hipertermijos-2","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/lt\/klinikinis-tyrimas-hipertermijos-2\/","title":{"rendered":"Gili regionin\u0117 hipertermija kartu su vis\u0173 smegen\u0173 radioterapija (WBRT) blogos prognoz\u0117s pacientams, sergantiems smegen\u0173 metastaz\u0117mis"},"content":{"rendered":"<h1 style=\"text-align: center;\">\u00a0<a href=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Deep-regional-hyperthermia-in-combination-with-whole-brain-radiotherapy-wbrt-in-poor-prognosis-patients-with-brain-metastases.pdf\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Gili regionin\u0117 hipertermija kartu su vis\u0173 smegen\u0173 radioterapija (WBRT) blogos prognoz\u0117s pacientams, sergantiems smegen\u0173 metastaz\u0117mis<\/span><\/span><\/a><\/h1>\n<h2 style=\"text-align: center;\">klinikinis tyrimas<\/h2>\n<figure id=\"attachment_6979\" aria-describedby=\"caption-attachment-6979\" style=\"width: 567px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-6979 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2017\/08\/Deep-local-hyperthermia-in-combination-with-Whole-Brain-RadioTherapy-WBRT-in-Poor-Prognosis-Patients-with-Brain-Metastases.jpg\" alt=\"Klinikinis tyrimas. Gili lokali hipertermija kartu su viso smegen\u0173 spindulin\u0117s terapijos (WBRT) taikymu blogos prognoz\u0117s pacientams, sergantiems smegen\u0173 metastaz\u0117mis.\" width=\"567\" height=\"776\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2017\/08\/Deep-local-hyperthermia-in-combination-with-Whole-Brain-RadioTherapy-WBRT-in-Poor-Prognosis-Patients-with-Brain-Metastases.jpg 567w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2017\/08\/Deep-local-hyperthermia-in-combination-with-Whole-Brain-RadioTherapy-WBRT-in-Poor-Prognosis-Patients-with-Brain-Metastases-219x300.jpg 219w\" sizes=\"auto, (max-width: 567px) 100vw, 567px\" \/><figcaption id=\"caption-attachment-6979\" class=\"wp-caption-text\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Gili lokali hipertermija kartu su viso smegen\u0173 spindulin\u0117s terapijos (WBRT) taikymu blogos prognoz\u0117s pacientams, sergantiems smegen\u0173 metastaz\u0117mis<\/span><\/span><\/figcaption><\/figure>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Klinikinio tyrimo <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">santrauka<\/span><\/span><\/strong><\/h2>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tikslas:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u0160io klinikinio tyrimo tikslas \u2013 pirm\u0105 kart\u0105 \u012fvertinti regionin\u0117s giliosios hipertermijos, taikomos kartu su radioterapija ir sistemine terapija, vaidmen\u012f pacientams, kuriems yra prastos progresijos smegen\u0173 metastaz\u0117s (GPI\u22642,5).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Metodai:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u012e \u0161\u012f prospektyvin\u012f tyrim\u0105 buvo \u012ftraukti pacientai, kuriems patvirtintos metastaz\u0117s smegenyse ir kuri\u0173 GPI balas buvo \u22642,5. Prie\u0161 gydym\u0105 pacientai buvo suskirstyti \u012f grupes, kuri\u0173 GPI balas buvo 0\u20131 (A grup\u0117), ir pacientus, kuri\u0173 GPI balas buvo 1,5\u20132,5 (B grup\u0117). Hipertermija (HT) buvo taikoma du kartus per savait\u0119, \u0161e\u0161iasde\u0161imt minu\u010di\u0173 per seans\u0105, spindulin\u0117s terapijos metu, naudojant regionin\u012f talpin\u012f prietais\u0105 ( <\/span><\/span><a href=\"http:\/\/andromedic.it\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u201eAndromedic <\/span><\/span><\/a> <a href=\"https:\/\/andromedichyperthermia.com\/andromedic-hydeep-600wm-deep-local-hyperthermia-device-2\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HyDeep 600WM\u201c hipertermijos prietais\u0105<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ) 13,56 MHz radijo da\u017eniu.<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rezultatai:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Nuo 2015 m. bir\u017eelio m\u0117n. iki 2017 m. bir\u017eelio m\u0117n. \u012f protokol\u0105 buvo \u012ftraukti 15 pacient\u0173 ir i\u0161 viso 49 metastaz\u0117s smegenyse. Visiems pacientams buvo atlikti visi HT seansai, kaip planuota. RT ir sistemin\u0117 terapija taip pat buvo atliekama pagal paskirt\u0105 tvark\u0105. <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Toleravimas gydymui buvo puikus ir nebuvo u\u017eregistruota jokio toksinio poveikio. Pacientams, kuriems HT veiksmingas gydymas truko ilgiau nei mediana (W90time &gt; 88%), aktuarinis PFS buvo geresnis po 6 ir 12 m\u0117nesi\u0173 (atitinkamai 100% ir 66,7%), palyginti su tais, kuriems HT veiksmingas gydymas truko trumpiau (atitinkamai 50% ir 0%)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (p &lt; 0,031). Vidutinis bendras i\u0161gyvenamumas buvo 6 m\u0117nesiai (nuo 1 iki 36 m\u0117nesi\u0173). Stratifikacija pagal GPI bal\u0105 parod\u0117, kad A grup\u0117je vidutinis bendras i\u0161gyvenamumas buvo 3 m\u0117nesiai (PI 95% 2,49\u20133,51), o B grup\u0117je \u2013 8,0 m\u0117nesiai (PI 95% 5,1510,41) (p = 0,035).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">I\u0161vados: <\/span><\/span><\/strong> <strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">regionin\u0117 hipertermija yra \u012fmanoma ir saugi technika, taikoma kartu su spinduline terapija pacientams, kuriems yra metastazi\u0173 smegenyse, pagerinanti ligos progresavimo nebuvim\u0105 ir i\u0161gyvenamum\u0105 pacientams, kuriems yra blogos prognoz\u0117s metastazi\u0173 smegenyse.<\/span><\/span><\/strong><\/p>\n<p>&nbsp;<\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">M\u016bs\u0173 tyrime buvo \u012ftrauktos 49 smegen\u0173 metastaz\u0117s i\u0161 15 pacient\u0173, priklausan\u010di\u0173 nepalankiausioms GPA grup\u0117ms: 6 pacient\u0173 bal\u0173 indeksas buvo 0\u20131 (A grup\u0117), o 9 pacient\u0173 \u2013 1,5\u20132,5 (B grup\u0117). Visiems pacientams buvo taikomas radioterapijos ir regionin\u0117s histologin\u0117s terapijos (HT) derinys. Pirmoji m\u016bs\u0173 tyrimo i\u0161vada yra ta, kad kombinuota radioterapija ir regionin\u0117 histologin\u0117 terapija yra gerai toleruojamas gydymas pacientams, patyrusiems metastazes smegenyse. Visi gydymo b\u016bdai buvo skirti kaip paskirta <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">.<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Nebuvo u\u017eregistruotas joks HT toksinis poveikis. Prie\u0161ingai, Byun ir kt. [13] savo tyrime su intraoperaciniu HT apra\u0161\u0117 traukulius ir \u017eaizd\u0173 infekcij\u0105 kaip kombinuoto gydymo komplikacijas atitinkamu skai\u010diumi atvej\u0173. <\/span><\/span><\/strong> <strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Gilioji hipertermija, atrodo, yra lengviau ir saugiau taikyti nei sud\u0117tingas intraoperacinis gydymas<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT gydymo kokyb\u0117 (W90time &gt;88%) l\u0117m\u0117 stipriausi\u0105 i\u0161gyvenamumo prediktyv\u0173 veiksn\u012f. Taigi pacientams, kurie &gt;88% gydymo laiko gavo 90% paskirtos galios (150 W), buvo puik\u016bs i\u0161gyvenamumo be ligos progresavimo rodikliai, o tai patvirtina HT vaidmen\u012f didinant navik\u0173 jautrum\u0105 radiochemoterapijai [4-7].<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Remiantis bendro i\u0161gyvenamumo rodikliais, m\u016bs\u0173 serijoje vidutin\u0117 bendro i\u0161gyvenamumo trukm\u0117 buvo 6 m\u0117nesiai, o tai pagerino prastus standartinio gydymo rezultatus \u0161iais atvejais [3]. Hipertermijos ir sisteminio spindulin\u0117s terapijos (RT+\/-) ry\u0161ys pasiek\u0117 53,1 % tikimyb\u0119 i\u0161gyventi po 6 m\u0117nesi\u0173 ir 30,6 % tikimyb\u0119 po 12 m\u0117nesi\u0173 m\u016bs\u0173 pacientams, kuriems buvo metastaz\u0117s smegenyse ir kaul\u0173 \u010diulpuose<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">https:\/\/pubmed.ncbi.nlm.nih.gov\/32748093\/<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">https:\/\/link.springer.com\/article\/10.1007\/s12094-020-02404-9<\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0Gili regionin\u0117 hipertermija kartu su vis\u0173 smegen\u0173 radioterapija (WBRT) blogos prognoz\u0117s pacientams, sergantiems smegen\u0173 metastaz\u0117mis klinikinis tyrimas Klinikinio tyrimo santrauka Tikslas: \u0160io klinikinio tyrimo tikslas \u2013 pirm\u0105 kart\u0105 \u012fvertinti regionin\u0117s giliosios hipertermijos, taikomos kartu su radioterapija ir sistemine terapija, vaidmen\u012f pacientams, kuriems yra prastos progresijos smegen\u0173 metastaz\u0117s (GPI\u22642,5). Metodai: \u012e \u0161\u012f prospektyvin\u012f tyrim\u0105 buvo \u012ftraukti&hellip;<\/p>\n","protected":false},"author":1,"featured_media":7047,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[173],"tags":[],"class_list":["post-4299","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-lt"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/posts\/4299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/comments?post=4299"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/posts\/4299\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/media\/7047"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/media?parent=4299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/categories?post=4299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/tags?post=4299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}